Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840116 | 0.88 | MAPK14 (0.44) | MAPK14CYP2D6CYP2C19CYP2C9OPRM1 | |
| SCHEMBL4872279 | 0.88 | MAPK14 (0.56) | MAPK14CYP2D6CYP2C19CYP2C9OPRM1 | |
| SCHEMBL4830537 | 0.86 | MAPK14 (0.42) | MAPK14CYP2D6OPRD1 | |
| SCHEMBL4494523 | 0.81 | MAPK14 (0.54) | MAPK14CYP2D6CYP2C19CYP2C9POLB | |
| SCHEMBL4841808 | 0.79 | MAPK14 (0.54) | MAPK14 | |
| SCHEMBL14109846 | 0.79 | MAPK14 (0.47) | MAPK14OPRM1OPRD1 | |
| SCHEMBL4502922 | 0.75 | MAPK14 (0.42) | MAPK14OPRM1OPRD1 | |
| SCHEMBL4493311 | 0.73 | MAPK14 (0.44) | MAPK14OPRM1OPRD1 | |
| SCHEMBL4505028 | 0.72 | MAPK14 (0.64) | MAPK14OPRM1OPRD1 | |
| SCHEMBL4493179 | 0.72 | MAPK14 (0.51) | MAPK14CYP2D6CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | MAPK14 21/4885CYP2D6 3069/4885CYP2C19 3348/4885 |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK4 | MAPK14 11/4885CYP2D6 2878/4885CYP2C19 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.